Aleniglipron
Phase 3Small molecule
Aleniglipron is one of 89 small molecule programs targeting Obesity. It is currently in Phase 3.
2
Indications
4
Total Trials
3
Active Trials
88
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
190 competitors in Obesity
#DrugCompanyPhaseTrials
1Synthroid
IInstitut Jerome Lejeune
Phase 3
NNC0487-0111
Novo NordiskPhase 3
IBI362
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Gemtesa
Sumitomo Pharma America, Inc.Phase 3
Zenagamtide
Novo NordiskPhase 3
Elecoglipron
AstraZenecaPhase 3
Belantamab Mafodotin-Blmf
Novo NordiskPhase 3
Efsubaglutide Alfa
SShanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Phase 3
Aleniglipron
GGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase 3
Avapro
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Obesity2 trials
A Long-Term Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Multiple Maintenance Doses of Oral Once Daily Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Recruiting·GGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics·Phase 3·NCT07654374·1,100 enrolled
A Randomized, Double-Blind, Placebo-Controlled, Pivotal Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of Multiple Maintenance Doses of Once Daily Oral Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and a Weight-Related Comorbidity
Recruiting·GGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics·Phase 3·NCT07654361·3,600 enrolled
Type 2 Diabetes Mellitus1 trial
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
Recruiting·GGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics·Phase 2·NCT07400588·50 enrolled
Obesity, Overweight, or Chronic Weight Management1 trial
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity (Body Mass Index ≥ 30 kg/m2) or Overweight (Body Mass Index ≥ 27 kg/m2) With at Least One Weight-related Comorbidity
Completed·GGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics·Phase 2·NCT06693843·230 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Aleniglipron. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details